Avicanna Inc. (AVCNF)
| Market Cap | 28.64M |
| Revenue (ttm) | 18.43M |
| Net Income (ttm) | -5.03M |
| Shares Out | n/a |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,500 |
| Open | 0.283 |
| Previous Close | 0.275 |
| Day's Range | 0.283 - 0.283 |
| 52-Week Range | 0.168 - 0.532 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 31, 2025 |
About Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific... [Read more]
Full Company ProfileFinancial Performance
In 2023, Avicanna's revenue was 16.79 million, an increase of 314.82% compared to the previous year's 4.05 million. Losses were -8.74 million, -40.67% less than in 2022.
Financial numbers in CAD Financial StatementsNews
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company
Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch Cosmetic registration and delivery into Germany completed in preparation for the initial comm...
Avicanna Reports Q3 2024
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024.
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LA...
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCIC 1000 patient ...
Avicanna Announces Repayment of Debentures
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
USPTO issues Patent No. US 20230025693A1 (“ Patent ”) that covers Avicanna's deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
19th international market for Aureus branded products and 22nd market for all Avicanna products 19th international market for Aureus branded products and 22nd market for all Avicanna products
Avicanna Reports Q2 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023 Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain
Avicanna Announces Changes of Auditors
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and c...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
This marks the first export into Asia, the 18 th international market for Aureus branded products and 21 st market for all Avicanna products
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and ...
Avicanna General Meeting
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and c...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna's self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain Patent No. US 11,998,632 ...
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
Investors, advisors and analysts, will have the opportunity to attend in-person or participate online at VirtualInvestorConferences.com Investors, advisors and analysts, will have the opportunity to a...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company's History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunero...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch. 55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability.
Avicanna Announces Closing of Non-brokered Private Placement
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation The study results revealed improvements in symptoms and quality of life i...
Avicanna Inc. (AVCNF) Q4 2023 Earnings Call Transcript
Avicanna Inc. (OTCQX:AVCNF) Q4 2023 Earnings Call Transcript April 2, 2024 8:30 AM ET Company Participants Aras Azadian - Chief Executive Officer Phillip Cardella - Chief Financial Officer Conference ...
Avicanna Reports Full Year 2023 Audited Financial Results
$16.8M in Revenue, representing an increase of 314% from 2022 $6.7M Consolidated gross Profit, representing an increase of 500% from 2022
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation
The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIR...
Avicanna To Hold Full Year 2023 Earnings Conference Call
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and co...
Avicanna Hosts Symposium on Cannabinoid-based Medicine
Symposium seeks to bring Key Opinion Leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption from the MaRS Discovery District, Toronto Symposium seeks to br...
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
Research will assess the combination of Avicanna's proprietary SEDDS technology in various drug delivery systems and dosage forms Research will assess the combination of Avicanna's proprietary SEDDS t...
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) Approval issued by the Health Auth...